phenelzine and Amerge Interactions

Interactions between phenelzine and Amerge (naratriptan)

phenelzine and naratriptan (Major Drug-Drug)

GENERALLY AVOID: The 5-HT1 receptor agonists used to treat migraine headaches exhibit modest 5-HT1A activity. Theoretically, MAOIs may potentiate the serotonergic activity of 5-HT1 receptor agonists and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A receptors. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of serotonin metabolism.

MANAGEMENT: The concomitant use of 5-HT1 receptor agonists and MAOIs or other agents which possess MAOI activity (e.g., furazolidone, procarbazine, selegiline) should be avoided if possible. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with 5-HT1 receptor agonists. If concurrent therapy is necessary, the patient should be closely monitored for adverse effects related to excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.